Weil advised its longstanding client Biofarma, an Ardian portfolio company, in connection with its successful issuance of €500 million senior secured floating rate notes due 2029 and $110,638,300 senior secured floating rate privately placed notes due 2029.

Weil has also advised Biofarma on the establishment of a new €135 million revolving credit facility and a delayed draw facility of up to €200 million in the form of additional privately placed notes.

The proceeds of the offering of the notes will be used by Biofarma to refinance outstanding debt and for general corporate purposes.

Biofarma is a leading global contract development and manufacturing organization (“CDMO”) specialized in the development, manufacturing and packaging of nutraceuticals (comprising food supplements and medical devices) and cosmetics.

The Weil team was led by High Yield partner Gilles Teerlinck and included High Yield associates Lorenzo Colombi-Manzi and Roberto Storlazzi, Finance partner Tom Richards, Finance counsel Kai Zhang and Oliver Trotman, and Finance associate Stephen Bhasera. The team was also supported by U.S. Banking & Finance partner Paul Overmyer and associates Kateryna Mekianov and Julia Pjevach on the U.S. finance aspects and Tax partner Devon Bodoh and associate Carlos Parra on the U.S. tax aspects.